You are here

FDA Approves Ribasphere for the Treatment of Chronic Hepatitis C

CRANBERRY TOWNSHIP, Pa., April 7 /PRNewswire/ -- Three Rivers Pharmaceuticals, LLC today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for its Ribasphere(TM) (Ribavirin capsules) 200mg in combination with interferon alfa-2b for the treatment of Hepatitis C ("HCV").

The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, "The approval of Ribasphere(TM) marks a milestone in the treatment of HCV. Ribasphere(TM) is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease." Traditionally the cost of treatment for HCV can range from $20,000 - $25,000 annually. "Our aim is to bring affordable medicine to all individuals infected with this dreadful disease," Mr. Kerrish continued.

"This victory for the approval of Ribasphere(TM) did not come without a great deal of pain and persistence on the legal and regulatory fronts," said Paul F. Fagan, Executive Vice President and General Counsel of Three Rivers. The ANDA was filed with the FDA in July of 2001. During the past 33 months, Three Rivers has successfully battled multiple patent infringement lawsuits and overcome significant regulatory issues that both delayed and complicated the entry of Ribasphere(TM) into the marketplace. Both Mr. Kerrish and Mr. Fagan agreed that enduring the long and complex process has been well worth it. They will now be able to see patients benefit from the fruits of the company's labor.

Hepatitis C affects nearly 4 million Americans and 170 million people worldwide. HCV is responsible for 8,000 to 10,000 deaths per year in the United States and is the number one cause of liver transplants. HCV can also lead to cirrhosis, end-stage liver disease, and liver cancer. Over 30,000 new cases are diagnosed each year.

Source: Three Rivers Pharmaceuticals

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation